HC Wainwright Reiterates “Buy” Rating for Vascular Biogenics (VBLT)
Vascular Biogenics (NASDAQ:VBLT)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report issued on Monday. They presently have a $3.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 160.87% from the stock’s current price.
The analysts wrote, “We reiterate our Buy rating of VBLT and our 12-month price target of $3.00 per share. We derive our price target based on the average of two valuation methods: (1) price-sales multiple analysis applying an 6x multiple to our 2026 sales estimate discounted at 18%; and (2) price-earnings multiple analysis applying an 19x multiple to our 2026 estimated earnings discounted at 18%. (1) clinical; (2) regulatory; (3) commercial; (4) partnership; (5) financial; and (6) intellectual property.””
Separately, Zacks Investment Research raised shares of Vascular Biogenics from a “hold” rating to a “buy” rating and set a $1.75 price target for the company in a research note on Thursday, August 23rd. Five equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Vascular Biogenics presently has an average rating of “Hold” and a consensus price target of $2.94.
A hedge fund recently bought a new stake in Vascular Biogenics stock. First Republic Investment Management Inc. purchased a new position in shares of Vascular Biogenics Ltd (NASDAQ:VBLT) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 270,000 shares of the biopharmaceutical company’s stock, valued at approximately $438,000. First Republic Investment Management Inc. owned approximately 0.75% of Vascular Biogenics as of its most recent SEC filing. Hedge funds and other institutional investors own 16.36% of the company’s stock.
About Vascular Biogenics
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
Featured Story: What are no-load funds?
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.